Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
J Psychiatr Res ; 175: 323-332, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38759498

RESUMO

Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis represents one of the most consistent pathophysiological findings in depressive disorders. Cortisol signaling is affected by proteins that mediate its cellular responses or alters its availability to mineralocorticoid and glucocorticoid receptors. In our study, we evaluated candidate genes that may influence the risk for depression and suicide due to its involvement in cortisol signaling. The aim of the study was to assess whether the genotypes of these genes are associated with the risk for depression, severity of depressive symptoms, suicidal ideation, and suicide attempts. And whether there is interaction between genes and early-life stress. In this study, 100 healthy controls and 140 individuals with depression were included. The subjects were clinically assessed using the 21-item GRID-Hamilton questionnaires (GRID-HAMD-21), Beck Scale for Suicidal Ideation (BSI), and the Childhood Trauma Questionnaire (CTQ). A robust multifactorial dimensionality reduction analysis was used to characterize the interactions between the genes HSD11B1, NR3C1, NR3C2, and MDR1 and early-life stress. It was found a significant association of the heterozygous genotype of the MDR1 gene rs1128503 polymorphism with reduced risk of at least one suicide attempt (OR: 0.08, p = 0.003*) and a reduction in the number of suicide attempts (ß = -0.79, p = 0.006*). Furthermore, it was found that the MDR1 rs1228503 and NR3C2 rs2070951 genes interact with early-life stress resulting in a strong association with depression (p = 0.001). Our findings suggest that polymorphisms in the MDR1 and NR3C2 genes and their interaction with childhood trauma may be important biomarkers for depression and suicidal behaviors.


Assuntos
Epistasia Genética , Hidrocortisona , Receptores de Glucocorticoides , Receptores de Mineralocorticoides , Ideação Suicida , Tentativa de Suicídio , Humanos , Feminino , Masculino , Adulto , Receptores de Glucocorticoides/genética , Hidrocortisona/metabolismo , Receptores de Mineralocorticoides/genética , Experiências Adversas da Infância , Subfamília B de Transportador de Cassetes de Ligação de ATP/genética , Depressão/genética , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único , Adulto Jovem , Estresse Psicológico/genética , Predisposição Genética para Doença
2.
Behav Brain Res ; 381: 112343, 2020 03 02.
Artigo em Inglês | MEDLINE | ID: mdl-31704233

RESUMO

The hypothalamic-pituitary-adrenal axis has been implicated in the pathophysiology of depressive disorders. HSD11B1 encodes 11ß-hydroxysteroid dehydrogenase type1 enzyme, responsible for converting cortisone to cortisol. Genetic polymorphisms in HSD11B1 may impact in depression outcome and risk of suicide. This study aimed to assess whether HSD11B1 genotypes and haplotypes are associated with depression risk, severity of symptoms and suicidal attempts, considering early-life stress as an environmental factor. Here, 142 depressive patients and 103 healthy controls were included. Patients were enrolled from the Affective Disorders ambulatory and day hospital units, both within the University General Hospital of Ribeirao Preto. All subjects were clinically assessed applying the Mini-PLUS International Neuropsychiatric Interview, followed by the 21-item GRID-Hamilton Depression Scale, Childhood Trauma Questionnaire and Beck Scale for Suicidal Ideation (BSI). All subjects underwent antecubital vein puncture to obtain blood for DNA extraction. Genotyping of rs11119328 and rs11811440 were performed using allele-specific oligonucleotide polymerase chain reaction. We found a significant association of rs11119328 variant genotypes with increased risk for at least one suicide attempt (OR: 7.10, p = 0.049) and an association of variant genotypes of rs11811440 with euthymic mood under optimized pharmacological treatment (OR: 0.05, P = 0.014). These tests included correction for confounding factors. The association of genetic markers with depression risk, GRID-HAM-D21 and BSI scores and the number of suicidal attempts were nonsignificant. Haplotypes combining both markers were not associated with the studied phenotypes. We conclude that HSD11B1 polymorphisms may be relevant biomarkers for detecting subjects genetically vulnerable to poorer antidepressant response and higher risk of suicide attempts.


Assuntos
11-beta-Hidroxiesteroide Desidrogenase Tipo 1/genética , Antidepressivos/uso terapêutico , Transtorno Depressivo/tratamento farmacológico , Tentativa de Suicídio , 11-beta-Hidroxiesteroide Desidrogenase Tipo 1/metabolismo , Adulto , Estudos de Casos e Controles , Feminino , Predisposição Genética para Doença , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Masculino , Pessoa de Meia-Idade , Sistema Hipófise-Suprarrenal/metabolismo , Polimorfismo Genético , Polimorfismo de Nucleotídeo Único , Resultado do Tratamento , Adulto Jovem
3.
Behav Brain Res ; 357-358: 48-56, 2019 01 14.
Artigo em Inglês | MEDLINE | ID: mdl-29702176

RESUMO

INTRODUCTION: Borderline Personality Disorder (BPD) and Bipolar Affective Disorder (BD) have clinical characteristics in common which often make their differential diagnosis difficult. The history of early life stress (ELS) may be a differentiating factor between BPD and BD, as well as its association with clinical manifestations and specific neuroendocrine responses in each of these diagnoses. OBJECTIVE: Assessing and comparing patients with BD and BPD for factors related to symptomatology, etiopathogenesis and neuroendocrine markers. METHODOLOGY: The study sample consisted of 51 women, divided into 3 groups: patients with a clinical diagnosis of BPD (n = 20) and BD (n = 16) and healthy controls (HC, n = 15). Standardized instruments were used for the clinical evaluation, while the history of ELS was quantified with the Childhood Trauma Questionnaire (CTQ), and classified according to the subtypes: emotional abuse, physical abuse, sexual abuse, emotional neglect and physical neglect. The functioning of the hypothalamic-pituitary-adrenal (HPA) axis was evaluated by measuring a single plasma cortisol sample. RESULTS: Patients with BPD presented with more severe psychiatric symptoms of: anxiety, impulsivity, depression, hopelessness and suicidal ideation than those with BD. The history of ELS was identified as significantly more prevalent and more severe in patients (BPD and BP) than in HC. Emotional abuse, emotional neglect and physical neglect also showed differences and were higher in BPD than BD patients. BPD patients had greater severity of ELS overall and in the subtypes of emotional abuse, emotional neglect and physical neglect than BD patients. The presence of ELS in patients with BPD and BP showed significant difference with lower cortisol levels when compared to HC. The endocrine evaluation showed no significant differences between the diagnoses of BPD and BD. Cortisol measured in patients with BPD was significantly lower compared to HC in the presence of emotional neglect and physical neglect. A significant negative correlation between the severity of hopelessness vs cortisol; and physical neglect vs cortisol were found in BPD with ELS. The single cortisol sample showed a significant and opposite correlations in the sexual abuse diagnosis-related groups, being a negative correlation in BD and positive in BPD. DISCUSSION: Considering the need for a multi-factorial analysis, the differential diagnosis between BPD and BD can be facilitated by the study of psychiatric symptoms, which are more severe in the BPD patients with a history of early life stress. The function of the HPA axis assessed by this cortisol measure suggests differences between BPD and BP with ELS history. CONCLUSION: The integrated analysis of psychopathology, ELS and neuroendocrine function may provide useful indicators to differentiate BPD and BD diagnoses. These preliminary data need to be replicated in a more significant sample with improved and multiple assessments of HPA axis activity.


Assuntos
Transtorno Bipolar/sangue , Transtorno Bipolar/psicologia , Transtorno da Personalidade Borderline/sangue , Transtorno da Personalidade Borderline/psicologia , Hidrocortisona/sangue , Estresse Psicológico/fisiopatologia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escalas de Graduação Psiquiátrica , Psicometria , Adulto Jovem
4.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; Braz. J. Psychiatry (São Paulo, 1999, Impr.);26(3): 189-201, set. 2004. ilus, tab
Artigo em Português | LILACS | ID: lil-387869

RESUMO

OBJETIVO: As mudanças no eixo hipotálamo-pituitária-adrenal (HPA) são características da depressão. Devido aos efeitos dos glicocorticóides serem mediados por receptores intracelulares, como os receptores de glicocorticóides (RGs), inúmeros estudos examinaram o número e/ou função dos RGs em pacientes com depressão. MÉTODOS: Os autores fazem uma revisão das evidências científicas dos estudos que têm consistentemente demonstrado que a função dos RGs está prejudicada na depressão maior, em conseqüência da redução da resposta do eixo HPA ao feedback negativo mediado pelos RGs e a um aumento na produção e secreção de HLC em várias regiões cerebrais, sugerindo que esses mecanismos estão envolvidos na etiologia da depressão e no tratamento antidepressivo. RESULTADOS: Esta revisão faz um resumo da literatura atual sobre RG na depressão e sobre o impacto dos antidepressivos nos RGs em estudos clínicos e pré-clínicos, e dá suporte ao conceito de que a sinalização deficiente dos RGs é parte fundamental na fisiopatogenia da depressão, na ausência de evidências claras de redução na expressão dos RGs. Embora os efeitos dos antidepressivos nos hormônios glicocorticóides e seus receptores sejam relevantes para a ação terapêutica dessas drogas, os mecanismos moleculares subjacentes a esses efeitos ainda não estão esclarecidos. Estudos indicam que os antidepressivos têm efeitos diretos nos RGs, levando a uma melhora da função e a um aumento da expressão dos RGs. Nós propomos que, em humanos, os antidepressivos podem inibir os transportadores de esteróides localizados na barreira hemato-liquórica e nos neurônios, como o complexo de resistência a múltiplas drogas glicoproteína-p ("multidrug resistance p-glycoprotein"), e podem aumentar o acesso do cortisol ao cérebro e o feedback negativo mediado por glicocorticoides no eixo HPA. CONCLUSÃO: O aumento da ação do cortisol no cérebro pode ser uma abordagem eficaz para maximizar os efeitos terapêuticos dos antidepressivos. Hipóteses referentes aos mecanismos destes receptores envolvem compostos não esteróides que regulam a função dos RGs via segundos mensageiros. A pesquisa nesta área trará novos entendimentos à fisiopatologia e ao tratamento dos transtornos afetivos, em especial na depressão.


Assuntos
Humanos , Depressão/fisiopatologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Sistema Hipófise-Suprarrenal/fisiopatologia , Receptores de Glucocorticoides/fisiologia , Antidepressivos/farmacologia , Química Encefálica/efeitos dos fármacos , Química Encefálica/fisiologia , Depressão/metabolismo , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/metabolismo , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/metabolismo , Receptores de Glucocorticoides/efeitos dos fármacos
5.
Braz J Psychiatry ; 26(3): 189-201, 2004 Sep.
Artigo em Português | MEDLINE | ID: mdl-15645065

RESUMO

OBJECTIVES: Changes in the hypothalamic-pituitary-adrenocortical (HPA) system are characteristic of depression. Because the effects of glucocorticoids are mediated by intracellular receptors including, most notably, the glucocorticoid receptor (GR), several studies have examined the number and/or function of GRs in depressed patients. METHODS: Review scientific evidences have consistently demonstrated that GR function is impaired in major depression, resulting in reduced GR-mediated negative feedback on the HPA axis and increased production and secretion of CRF in various brain regions postulated to be involved in the causality of depression. RESULTS: This article summarizes the literature on GR in depression and on the impact of antidepressants on the GR in clinical and preclinical studies, and supports the concept that impaired GR signalling is a key mechanism in the pathogenesis of depression, in the absence of clear evidence of decreased GR expression. The data also indicate that antidepressants have direct effects on the GR, leading to enhanced GR function and increased GR expression. Although the effects of antidepressants on glucocorticoid hormones and their receptors are relevant for the therapeutic action of these drugs, the molecular mechanisms underlying these effects are unclear. We propose that antidepressants in humans could inhibit steroid transporters localised on the blood-brain barrier and in neurones, like the multidrug resistance p-glycoprotein, and thus increase the access of cortisol to the brain and the glucocorticoid-mediated negative feedback on the HPA axis. CONCLUSION: Enhanced cortisol action in the brain might prove to be a successful approach to maximise therapeutic antidepressant effects. Hypotheses regarding the mechanism of these receptor changes involve non-steroid compounds that regulate GR function via second messenger pathways. Research in this field will lead to new insights into the pathophysiology and treatment of affective disorders.


Assuntos
Depressão/fisiopatologia , Sistema Hipotálamo-Hipofisário/fisiopatologia , Sistema Hipófise-Suprarrenal/fisiopatologia , Receptores de Glucocorticoides/fisiologia , Antidepressivos/farmacologia , Química Encefálica/efeitos dos fármacos , Química Encefálica/fisiologia , Depressão/metabolismo , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Sistema Hipotálamo-Hipofisário/metabolismo , Sistema Hipófise-Suprarrenal/efeitos dos fármacos , Sistema Hipófise-Suprarrenal/metabolismo , Receptores de Glucocorticoides/efeitos dos fármacos
6.
Acta Neuropsychiatr ; 15(6): 354-67, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26983771

RESUMO

Changes in the hypothalamic-pituitary-adrenocortical (HPA) system are characteristic of depression, and in the majority of these patients these result in HPA axis hyperactivity. This is further supported by the reduced sensitivity to the inhibitory effects of the glucocorticoid, dexamethasone (DEX), on the production of adrenocorticotropic hormone (ACTH) and cortisol, during the DEX suppression test and the DEX-corticotropin-releasing hormone (DEX/CRH) test. Because the effects of glucocorticoids are mediated by intracellular receptors including, most notably, the glucocorticoid receptor (GR), several studies have examined the number and/or function of GRs in depressed patients. These studies have consistently demonstrated that GR function is impaired in major depression, resulting in reduced GR-mediated negative feedback on the HPA axis and increased production and secretion of CRH in various brain regions postulated to be involved in the causality of depression. This article summarizes the literature on GR in depression and on the impact of antidepressants on the GR in clinical and preclinical studies, and supports the concept that impaired GR signaling is a key mechanism in the pathogenesis of depression, in the absence of clear evidence of decreased GR expression. The data also indicate that antidepressants have direct effects on the GR, leading to enhanced GR function and increased GR expression. Hypotheses regarding the mechanism of these receptor changes involve non-steroid compounds that regulate GR function via second messenger pathways, such as cytokines and neurotransmitters. Moreover, we present recent evidence suggesting that membrane steroid transporters such as the multidrug resistance (MDR) p-glycoprotein, which regulate access of glucocorticoids to the brain, could be a fundamental target of antidepressant treatment. Research in this field will lead to new insights into the pathophysiology and treatment of affective disorders.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA